Objectives: To assess baseline differences on lipid profile in individuals with gender identity disorder (male to female, M2F and female to male, F2M) in relation to prior cross-sex hormone treatment (CHT) or not, and changes in the lipid profile after 24 months of treatment and follow-up in our unit.
Methods: Transversal study by revision of medical records of 235 patients visited for first time in our service from 2006 to 2010. Clinical and analytical revision was made on the first visit, 6, 12, and 24 months.
Results: At baseline, F2M (92 patients, 39%) transsexuals were younger than M2F (143 patients, 61%) (27.9±8.7 vs 32.0±9.8 years; P=0.03), they had lower triglycerides levels (68.8±29.7 vs 92.2±71.4 mg/dl; P=0.001) and higher HDL levels (51.4±12.3 vs 45.0±11.7 mg/dl; P<0.001). No differences in baseline lipid profile was observed between individuals with previous hormonal treatment versus naive in none of the two groups, but in M2F group, individuals with previous treatment had a higher weight (71.8±12.3 vs 67.0±12.1; P=0.038).
In M2F transsexuals group, at 24 months follow-up, we observed a significant increase in weight (71.1±13.0 vs 73.8±5.2 kg; P<0.001) and BMI (23.6±5.5 vs 24.5±6.3 kg/m2; P=0.001) without significant changes in the lipid profile.
On the other hand, at 24 months follow-up, in the F2M transsexuals group, we observed a significant increase in weight (67.2±13.6 vs 69.8±12.5 kg; P=0.005) and BMI (25.3±5.0 vs 26.4±4.1 kg/m2; P=0.002) and a worsening of lipid profile with increased total cholesterol (168.5±35.8 vs 178.2±37.9 mg/dl, P=0.003), triglycerides (71.7±31.4 vs 105.3±70.2 mg/dl; P<0.005), LDL (106.0±27.9 vs 115.2±29.1 mg/dl; P=0.018), no-HDL cholesterol (118.7±32.5 vs 136.3±34.1; P<0.000) and decrease in HDL (52.8±13.5 vs 45.4±14.5 mg/dl; P=0.001).
Conclusions: CHT leads to changes in lipid profile at 24 months, highlighting the worsening in F2M transsexuals.